share_log

Tevogen Bio Entered Into A Binding Term Sheet With An Existing Investor To Secure Up To $50M Of Financing

Benzinga ·  May 11 06:49
  • Supports expansion of Tevogen's ExacTcell platform toward additional clinical trials
  • Bolsters a financial path to positive cashflow and minimizes dilution

WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing.

This financing supports Tevogen Bio's pursuit of expanding research and development efforts with a focus on continued clinical development of the company's initial product, TVGN 489, from its ExacTcell technology platform. In January 2023, Tevogen Bio announced positive proof-of-concept clinical trial results of TVGN 489 for treatment of high-risk patients. The financing will also be utilized to facilitate Tevogen Bio's efforts to start additional clinical trials for virally induced cancers and multiple sclerosis.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment